ADAM17 and hepatocellular carcinoma: Based on this evidence, researchers investigated the use of ADAM17 inhibitors, such as ZLDI-8, showing their ability to prevent EMT in HCC cells by decreasing the release of Notch NICD, thereby improving the therapeutic efficacy of anticancer drugs [90,91,92].